Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.PMID:37926672 | DOI:10.1016/j.clml.2023.10.002

Source: Clinical Lymphoma and Myeloma - November 5, 2023 Category: Cancer & Oncology Authors: Carrie Ho Ajay K Gopal Brian G Till Mazyar Shadman Ryan C Lynch Andrew J Cowan Qian V Wu Jenna Voutsinas Heather A Rasmussen Katherine Blue Chaitra S Ujjani Ryan D Cassaday Jonathan R Fromm Min Fang Stephen D Smith Source Type: research